Arizona is currently home to 1681 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Phoenix, Tucson, Scottsdale and Mesa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
NCT06712407
Recruiting
The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg once daily treatment in real-world clinical practice. The main question it aims to answer is: Is there a treatment benefit of TARPEYO® 16 mg QD extended use? Participants will * take part in this study for about 19 months * Have urine tests done * Have blood samples... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Arizona Kidney Disease & Hypertension Centers (AKDHC), Glendale, Arizona
Conditions: IgA Nephropathy
Register for Updates
A Nutrition & Exercise Prehabilitation Intervention on Inflammatory Biomarkers in AI Cancer Patients
NCT06644560
Recruiting
The purpose of this study is to assess the feasibility of a prehab intervention among American Indian (AI) patients diagnosed with obesity-related cancer and measure inflammatory biomarkers to evaluate the preliminary impact of the trial intervention. The central hypothesis is that this community-informed prehab intervention will demonstrate feasibility, patient acceptability, and modulation of host and tumor-microenvironment inflammatory biomarkers. Aim 1: Implement the prehab translational cl... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/30/2025
Locations: University of Arizona Cancer Center, Tucson, Arizona
Conditions: Cancer, Obesity
Register for Updates
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
NCT06609005
Recruiting
This is a Phase 1a, first-in-human, open-label dose-escalation study to determine the RDR and/or MTD, and to assess the DLT of INV-9956. The safety, tolerability, PK/PD, and preliminary antitumor activity of INV-9956 will be assessed in adult patients with advanced mCRPC.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Honor Health, Scottsdale, Arizona
Conditions: Advanced Metastatic Castration Resistant Prostate Cancer
Register for Updates
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
NCT06433752
Recruiting
The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: TG Therapeutics Investigational Trial Site, Gilbert, Arizona
Conditions: Relapsing Multiple Sclerosis, Multiple Sclerosis
Register for Updates
Avapritinib With Decitabine in Patients With SM-AHN
NCT06327685
Recruiting
Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) is a challenging disease to treat. Targeted KIT inhibitors have been approved for this indication based on their ability to control the mastocytosis portion of the disease, but patients frequently experience progression of the concomitant myeloid malignancy (i.e. the AHN). Using a combination approach to treat both aspects of the disease has the potential to provide enhanced disease control; however, overlapping toxicity is a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Mayo Clinic - Arizona, Phoenix, Arizona
Conditions: Systemic Mastocytosis With an Associated Hematologic Neoplasm
Register for Updates
Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome
NCT06315751
Recruiting
This study is designed to evaluate the efficacy and safety of gemlapodect (NOE-105) on reducing tics associated with Tourette Syndrome (TS) in adults with TS. Adolescents will be enrolled after a sentinel cohort of adults is complete.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Noema TTS-201 Site #81, Sun City, Arizona
Conditions: Tourette Syndrome
Register for Updates
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06309966
Recruiting
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/30/2025
Locations: Xenoscience, Inc., Phoenix, Arizona
Conditions: Focal Epilepsy
Register for Updates
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT06290141
Recruiting
The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg. The study duration will be for a maximum of 109 weeks including screening, treatment phases, and follow-up.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Phoenix Neurological Associates - Phoenix- Site Number : 8400014, Phoenix, Arizona
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Register for Updates
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT06237452
Recruiting
The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo. The objectives and endpoints are identical for Stage 1 (recurrent CDI) and Stage 2 (high-risk primary CDI).
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/30/2025
Locations: Advanced Gastroenterology, P.C., Chandler, Arizona
Conditions: Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious
Register for Updates
Registry of the Patient Experience for Carpal Tunnel Release
NCT06071468
Recruiting
Multi-center study to collect large scale, multidimensional real-world data on patients undergoing carpal tunnel release (CTR).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Phoenix Hand (CTR-US), Scottsdale, Arizona
Conditions: Carpal Tunnel Syndrome, CTS
Register for Updates
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626
Recruiting
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main quest... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Mayo Clinic - Phoenix, Phoenix, Arizona
Conditions: Metastatic Breast Cancer
Register for Updates
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450
Recruiting
The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Research Site, Phoenix, Arizona
Conditions: Viral Lung Infection and Acute Respiratory Failure
Register for Updates